Literature DB >> 16009902

Distinguishing acute-onset CIDP from Guillain-Barré syndrome with treatment related fluctuations.

Liselotte Ruts1, Rinske van Koningsveld, Pieter A van Doorn.   

Abstract

Guillain-Barré syndrome (GBS) patients may worsen after initial treatment (treatment-related fluctuation [TRF]). It is difficult to distinguish GBS-TRF from chronic inflammatory demyelinating polyneuropathy with acute onset (A-CIDP). The authors compared 13 patients with A-CIDP with 11 patients with GBS-TRF and concluded that A-CIDP should be suspected when a patient with GBS deteriorates after 9 weeks from onset or when deterioration occurs three times or more. Maintenance treatment should then be considered.

Entities:  

Mesh:

Year:  2005        PMID: 16009902     DOI: 10.1212/01.wnl.0000167549.09664.b8

Source DB:  PubMed          Journal:  Neurology        ISSN: 0028-3878            Impact factor:   9.910


  22 in total

Review 1.  Advances in the diagnosis, pathogenesis and treatment of CIDP.

Authors:  Marinos C Dalakas
Journal:  Nat Rev Neurol       Date:  2011-08-16       Impact factor: 42.937

Review 2.  Immunomodulatory treatment other than corticosteroids, immunoglobulin and plasma exchange for chronic inflammatory demyelinating polyradiculoneuropathy.

Authors:  Mohamed Mahdi-Rogers; Ruth Brassington; Angela A Gunn; Pieter A van Doorn; Richard Ac Hughes
Journal:  Cochrane Database Syst Rev       Date:  2017-05-08

3.  Diagnostic value of anti-GQ1b antibodies in a patient with relapsing dysarthria and ataxia.

Authors:  Mark Kuijf; Liselotte Ruts; Pieter A van Doorn; Peter J Koudstaal; Bart C Jacobs
Journal:  BMJ Case Rep       Date:  2009-03-17

4.  Cerebrospinal fluid total protein in Guillain-Barré syndrome variants: correlations with clinical category, severity, and electrophysiology.

Authors:  Pierre R Bourque; J Brooks; J Warman-Chardon; A Breiner
Journal:  J Neurol       Date:  2019-11-16       Impact factor: 4.849

Review 5.  Newer therapeutic options for chronic inflammatory demyelinating polyradiculoneuropathy.

Authors:  Krista Kuitwaard; Pieter A van Doorn
Journal:  Drugs       Date:  2009-05-29       Impact factor: 9.546

6.  A Rare case of recurrent Guillain-Barré syndrome without albuminocytological dissociation.

Authors:  Anudeep Yelam; Elanagan Nagarajan; Raghav Govindarajan; Pradeep C Bollu
Journal:  BMJ Case Rep       Date:  2018-10-16

7.  Monocentric study of 28 cases of chronic inflammatory demyelinating polyneuropathy: first Tunisian study.

Authors:  Malek Mansour; Amine Rachdi; Nesrine Baradai; Amel Kacem; Ines Bedoui; Ridha Mrissa
Journal:  Neurol Sci       Date:  2021-05-04       Impact factor: 3.307

8.  Leukocyte oxygen radical production determines disease severity in the recurrent Guillain-Barré syndrome.

Authors:  Natalia Mossberg; Oluf Andersen; Magnus Nordin; Staffan Nilsson; Ake Svedhem; Tomas Bergström; Kristoffer Hellstrand; Charlotta Movitz
Journal:  J Inflamm (Lond)       Date:  2010-08-08       Impact factor: 4.981

Review 9.  Guillain-Barré and Miller Fisher syndromes--new diagnostic classification.

Authors:  Benjamin R Wakerley; Antonino Uncini; Nobuhiro Yuki
Journal:  Nat Rev Neurol       Date:  2014-07-29       Impact factor: 42.937

10.  Guillain-Barré Syndrome, Influenza Vaccination, and Antecedent Respiratory and Gastrointestinal Infections: A Case-Centered Analysis in the Vaccine Safety Datalink, 2009-2011.

Authors:  Sharon K Greene; Melisa D Rett; Claudia Vellozzi; Lingling Li; Martin Kulldorff; S Michael Marcy; Matthew F Daley; Edward A Belongia; Roger Baxter; Bruce H Fireman; Michael L Jackson; Saad B Omer; James D Nordin; Robert Jin; Eric S Weintraub; Vinutha Vijayadeva; Grace M Lee
Journal:  PLoS One       Date:  2013-06-26       Impact factor: 3.240

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.